OncoMatch/Clinical Trials/NCT06917079

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Is NCT06917079 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for non-small cell lung cancer.

Phase 1RecruitingTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)NCT06917079Data as of May 2026

Treatment: BBO-11818 · Pembrolizumab · Platinum chemotherapy (cisplatin or carboplatin) · Pemetrexed · Cetuximab · FOLFOX · NALIRIFOX · Gemcitabine · Nab-paclitaxel — A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Pancreatic Cancer

Colorectal Cancer

Tumor Agnostic

Biomarker criteria

Required: KRAS g12a

Required: KRAS g12c

Required: KRAS g12d

Required: KRAS g12s

Required: KRAS g12v

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

The Angeles Clinic and Research Institute - West Los Angeles Office · Los Angeles, California
University of California San Diego Moores Cancer Center · San Diego, California
Moffitt Cancer Center · Tampa, Florida
Massachusetts General Hospital · Boston, Massachusetts
NYU Langone Health · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify